Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AG Fatty acid derivatives
N03AG04 Vigabatrin
D00535 Vigabatrin (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
Gamma-aminobutyric Acid (GABA) Augmenting Agents
GABA Agents, Other
Vigabatrin
D00535 Vigabatrin (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1139 Others
D00535 Vigabatrin (JAN/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02037 GABA mimetic antiepileptic
D00535 Vigabatrin
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D00535 Vigabatrin
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Aminotransferase
ABAT
D00535 Vigabatrin (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00535
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00535
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00535
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00535
